A first-in-class bispecific antibody-drug conjugate that Bristol Myers Squibb paid $800 million for has shown strong phase 3 ...
Bristol Myers Squibb (BMY) looks undervalued: 4 near-term pipeline catalysts and DCF imply ~20% upside, plus 4.35% yield.
"ASCO26: BMS and J&J debut shining multiple myeloma data" was originally created and published by Pharmaceutical Technology, ...
Bristol Myers Squibb has high hopes for its celmod programme for blood cancers, and a phase 3 readout – for mezigdomide in ...
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 ...
Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.
A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance ...
Bristol Myers Squibb (NYSE: BMY) today announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial ( NCT05552976) of CELMoD (cereblon E3 ligase modulation) mezigdomide in combination ...
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with carfilzomib and dexamethasone (MeziKd ...
(ADCs) and multispecific antibodies for oncology. Under the terms of the mega-licensing and collaboration agreement, Pfizer and Suzhou, China-based Innovent agreed to codevelop and share costs for a ...
Halting the insidious accumulation of irreversible disability remains the principal challenge in multiple sclerosis care. Once classified as relapsing (including relapsing-remitting and active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results